Streptokinase treatment of cats with experimentally induced aortic thrombosis.
An investigation was initiated to determine the dosage of streptokinase (given IV) that would consistently produce systemic fibrinolysis, as determined by laboratory evaluation, and to determine the relative safety of this drug in the cat. Results indicated that a loading dose of 90,000 IU of streptokinase (given by continuous infusion over 20 to 30 minutes) and a maintenance dosage (IV) of 45,000 IU of streptokinase/hr predictably produced systemic fibrinolysis in the cat. There were no detectable adverse affects seen on physical examination, necropsy, or histopathologic examination. Using the foregoing dosage regimen, investigation was begun to evaluate the use of streptokinase for treatment of feline thromboembolism. Aortic thrombosis was created experimentally in 15 cats. There was no clearly predictable improvement in nonspecific venous angiograms or thermal circulatory indices for the cats given streptokinase, compared with the values for the control cats. After a total of 180 minutes of treatment, the mean weight of remaining clot removed at necropsy from the aortic trifurcation was 7.3 mg in the streptokinase-treated cats, compared with 13.4 mg in the control cats.
D000792:Angiography; D000818:Animals; D001018:Aortic Diseases / Q000188:drug therapy* / Q000662:veterinary; D001780:Blood Coagulation Tests / Q000662:veterinary; D002371:Cat Diseases / Q000097:blood / Q000188:drug therapy*; D002415:Cats; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D008297:Male; D013300:Streptokinase / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy* / Q000662:veterinary
D013300:Streptokinase